Quick Answer
Milk Thistle Cardiometabolic Randomized Trial has evidence relevant to strength of evidence and what the studies can or cannot prove, but conclusions should stay close to the cited sources. One representative finding is: Gut microbiota modulation was associated with improved sleep patterns, quality-of-life perception, cytokines expression, and anthropometric parameters post-supplementation.
Key Takeaways
- 01Gut microbiota modulation was associated with improved sleep patterns, quality-of-life perception, cytokines expression, and anthropometric parameters post-supplementation. [Santamarina AB (2024)]
- 02Nutraceutical interventions supporting microbiota and eliciting clinical improvements in metabolic diseases have grown significantly. [Santamarina AB (2024)]
- 03Chronic stress, gut dysbiosis, and metainflammation have emerged as key factors intertwined with sleep disorders, consequently exacerbating the decline in quality of life. [Santamarina AB (2024)]
- 04Material and methods We consecutively enrolled 80 mildly hypercholesterolemic patients with low-density lipoprotein-cholesterol (LDL-C) between 130 and 190 mg/dl with a low-estimated cardiovascular disease risk. [Fogacci F (2023)]
The current Migaku evidence database contains 2 reusable source documents for Milk Thistle Cardiometabolic Randomized Trial. This answer focuses on strength of evidence and what the studies can or cannot prove.
- Gut microbiota modulation was associated with improved sleep patterns, quality-of-life perception, cytokines expression, and anthropometric parameters post-supplementation. [Santamarina AB (2024); evidence level 2]
- Nutraceutical interventions supporting microbiota and eliciting clinical improvements in metabolic diseases have grown significantly. [Santamarina AB (2024); evidence level 2]
- Chronic stress, gut dysbiosis, and metainflammation have emerged as key factors intertwined with sleep disorders, consequently exacerbating the decline in quality of life. [Santamarina AB (2024); evidence level 2]
- Material and methods We consecutively enrolled 80 mildly hypercholesterolemic patients with low-density lipoprotein-cholesterol (LDL-C) between 130 and 190 mg/dl with a low-estimated cardiovascular disease risk. [Fogacci F (2023); evidence level 2]
- Introduction The scientific community and consumers are increasingly interested in the potential cholesterol-lowering effect of various nutraceuticals and their combinations. [Fogacci F (2023); evidence level 2]
Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording.
This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.
Sources
- Nutraceutical blends predict enhanced health via microbiota reshaping improving cytokines and life quality: a Brazilian double-blind randomized trial.
- Effect of dietary supplementation with a new nutraceutical formulation on cardiometabolic risk factors: a double-blind, placebo-controlled, randomized clinical study.